Diagnostics and Drug Delivery Devices

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM)

bioAffinity Technologies Reports 146% YoY Sales Growth of CyPath Lung in Q1 2026

bioAffinity Releases Clinical Case Study for CyPath Lung Test

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

BIAF

BIAFW

LABU

SBIO

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News

StockTitan

bioAffinity Tech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News

Earnings Watch

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 1.352 M

bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M

businessinsider

bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 1.352 M

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung | BIAF Stock News

iShares US Medical Devices

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung | BIAF Stock News

bioAffinity Technologies shares are trading higher after the company announced a pilot study evaluating its tests for chronic obstructive pulmonary disease in collaboration with Brooke Army Medical Center.

benzinga_article

bioAffinity Technologies, Inc. (Nasdaq: BIAF) has launched a pilot study in collaboration with Brooke Army Medical Center to evaluate its flow cytometry+AI diagnostic tests for asthma and COPD. The study aims to identify inflammatory biomarkers to tailor treatments for these respiratory diseases, which affect a significant market. Approximately 40 participants will be enrolled to analyze sputum samples for immune cell populations and cytokines. The goal is to enhance precision medicine in asthma and COPD management, particularly for military personnel, improving treatment outcomes and respiratory health.

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment | BIAF Stock News

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.162 M

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic

Tip Ranks

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM)(BIAFW.US)

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 1.352 M

bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 1.352 M

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung | BIAF Stock News

bioAffinity Technologies shares are trading higher after the company announced a pilot study evaluating its tests for chronic obstructive pulmonary disease in collaboration with Brooke Army Medical Center.

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment | BIAF Stock News

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.162 M

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic